Health Care [ 11/12 ] | Life Sciences Tools & Services [ 43/75 ]
NASDAQ | Common Stock
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.
The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.
Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.22 Increased by +82.26% | -0.42 Increased by +47.62% |
| May 8, 24 | -0.51 Decreased by -325.00% | -0.64 Increased by +20.31% |
| Mar 5, 24 | -0.96 Decreased by -637.92% | -0.87 Decreased by -10.26% |
| Nov 8, 23 | -1.00 Decreased by -809.09% | -0.97 Decreased by -3.09% |
| Aug 9, 23 | -1.24 Decreased by -1.03 K% | -1.03 Decreased by -20.39% |
| May 9, 23 | -0.12 Decreased by -9.09% | -0.11 Decreased by -9.09% |
| Mar 9, 23 | -0.13 Decreased by -62.50% | -0.11 Decreased by -18.18% |
| Nov 3, 22 | -0.11 Decreased by -57.14% | -0.11 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 7.77 M Decreased by -10.29% | -16.22 M Increased by +58.31% | Decreased by -208.78% Increased by +53.53% |
| Mar 31, 24 | 8.77 M Increased by +18.26% | -31.42 M Increased by +15.36% | Decreased by -358.33% Increased by +28.43% |
| Dec 31, 23 | 10.72 M Increased by +30.51% | -43.89 M Decreased by -13.48% | Decreased by -409.39% Increased by +13.04% |
| Sep 30, 23 | 9.32 M Increased by +29.04% | -112.57 M Decreased by -253.88% | Decreased by -1.21 K% Decreased by -174.24% |
| Jun 30, 23 | 8.66 M Increased by +29.87% | -38.91 M Decreased by -21.00% | Decreased by -449.23% Increased by +6.82% |
| Mar 31, 23 | 7.42 M Increased by +30.18% | -37.12 M Decreased by -23.94% | Decreased by -500.66% Increased by +4.79% |
| Dec 31, 22 | 8.21 M Increased by +30.36% | -38.68 M Decreased by -68.53% | Decreased by -470.81% Decreased by -29.29% |
| Sep 30, 22 | 7.22 M Increased by +55.12% | -31.81 M Decreased by -53.27% | Decreased by -440.51% Increased by +1.19% |